(1R,5R)-8-METHYL-8-AZABICYCLO[3.2.1]OCTAN-3-YL 3,3-DIPHENYLPROPANOATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MPDVPOAMVNWEEK-WOJBJXKFSA-N
Smiles	CN1[C@@H]2CC[C@@H]1CC(C2)OC(=O)CC(c3ccccc3)c4ccccc4
InChI	InChI=1S/C23H27NO2/c1-24-19-12-13-20(24)15-21(14-19)26-23(25)16-22(17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,19-22H,12-16H2,1H3/t19-,20-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H27NO2
Molecular Weight	349.47
AlogP	4.09
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	29.54
Molecular species	BASE
Aromatic Rings	2.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Insecticidal activity against Bombyx mori Shunrei x Shogetu fourth-instar larvae assessed as effect on larval growth at 100 ppm administered in diet relative to untreated control	Bombyx mori	None
Insecticidal activity against Bombyx mori Shunrei x Shogetu fourth-instar larva assessed as effect on larval molting at 160 ug/larvae upon topial application	Bombyx mori	None
Insecticidal activity against Bombyx mori Shunrei x Shogetu fourth-instar larva assessed as effect on larval growth at 160 ug/larvae upon topial application	Bombyx mori	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2271511

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).